MALVERN, Pa. & SAN DIEGO — PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company […]
PhaseBio Pharmaceuticals and BIOVECTRA Enter into Supply Agreement to Support Development and Commercialization of Bentracimab
Category: News
Major investment anchors alliance for bioscience skills and training in Atlantic Canada
Charlottetown, PE – Today the Future Skills Centre (FSC) announced the investment of $1.5 million to support the establishment of the Canadian Alliance for Skills […]
COVID-19: Our Obligation
\At BioVectra, we take our obligation as an essential service very seriously. […]
BIOVECTRA Inc. excited for continued growth under experienced CDMO investor, H.I.G. Capital
BioVectra Inc. excited for continued growth under experienced CDMO investor, H.I.G. Capital […]
Mallinckrodt Agrees to Sell BIOVECTRA Inc. to H.I.G. Capital for $250 Million
Statement from BIOVECTRA President, Oliver Technow, on BIOVECTRA’s sale to H.I.G. Capital: “We are very excited to enter into this new chapter with H.I.G. Capital! Under their stewardship we have a fantastic opportunity to continue building and growing our business right here in Atlantic Canada.” Official press release: Mallinckrodt Agrees to Sell BIOVECTRA Inc. to […]
BIOVECTRA Inc. hosts roundtable discussion with Minister Bernadette Jordan and other key Windsor community stakeholders to discuss planned five-year, $144.6 million expansion project
BIOVECTRA Inc. hosts roundtable discussion with Minister Bernadette Jordan and other key Windsor community stakeholders to discuss planned five-year, $144.6 million expansion project Windsor, Nova Scotia, Canada (March 7, 2019) – On March 6, 2019, BIOVECTRA Inc., an Atlantic Canadian Contract Development and Manufacturing Organization (CDMO), hosted a roundtable discussion at its Windsor, Nova Scotia […]
BIOVECTRA Inc. Announces the Offer of High Quality, Fully Synthetic cGMP Cannabidiol (CBD) Active Pharmaceutical Ingredient (API)
BIOVECTRA Inc. Announces the Offer of High Quality, Fully Synthetic cGMP Cannabidiol (CBD) Active Pharmaceutical Ingredient (API) Charlottetown, Prince Edward Island, Canada (March 17, 2019) – BIOVECTRA Inc., a U.S. Food and Drug Administration- and Health Canada-inspected and approved Contract Development and Manufacturing Organization (CDMO), announces the offer of high quality, fully synthetic cGMP CBD […]
BIOVECTRA Inc. Invests $1.5M in Large-Scale Synthetic Reactor Replacements and Analytical Development Capabilities
BIOVECTRA Inc. Invests $1.5M in Large-Scale Synthetic Reactor Replacements and Analytical Development Capabilities BIOVECTRA Inc., a global Contract Development and Manufacturing Organization (CDMO), today announced new investments in its large-scale synthetic chemistry and analytical development capabilities. To continue serving its client’s cGMP manufacturing needs, BIOVECTRA completed the replacement of two 4,000L vessels used for small […]
BIOVECTRA Inc. announces a $144.6 million expansion project, including a $37.5 million contribution through the Government of Canada’s Strategic Innovation Fund
BIOVECTRA Inc. announces a $144.6 million expansion project, including a $37.5 million contribution through the Government of Canada’s Strategic Innovation Fund — Prime Minister Justin Trudeau visits BIOVECTRA to announce Government of Canada investment in Atlantic Canadian CDMO and high-skilled jobs creation in the region — Charlottetown, Prince Edward Island, Canada (March 4, 2019) – […]
BIOVECTRA wins BIOTECanada’s Gold Leaf Award for Company of the Year!
CANADIAN BIOTECH INDUSTRY RECOGNIZES TOP PERFORMERS DURING GLOBAL BIOTECH WEEK September 26, 2018 [OTTAWA] – BIOTECanada is pleased to announce the 2018 winners of the Gold Leaf Awards which annually highlight innovation and entrepreneurship within the Canadian biotechnology industry. This national celebration of the Canadian industry represents an outstanding collection of companies and individuals who […]
